Healthcare - Biotechnology - NASDAQ - US
$ 9.47
-6.24 %
$ 563 M
Market Cap
-2.62
P/E
CASH FLOW STATEMENT
-192 M
OPERATING CASH FLOW
68.4 M
INVESTING CASH FLOW
115 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
IGM Biosciences, Inc.
| Net Income | -246 M |
| Depreciation & Amortization | 8.28 M |
| Capital Expenditures | -12.4 M |
| Stock-Based Compensation | 46.5 M |
| Change in Working Capital | -6.69 M |
| Others | 353 K |
| Free Cash Flow | -205 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (246.4) | (221.1) | (165.2) | (81.4) | (43.1) | (22.7) | (11.1) |
| Depreciation & Amortization | 8.3 | 6.1 | 4.5 | 1.0 | 0.6 | 0.3 | 0.2 |
| Deferred Income Tax | 0 | 0 | 0.8 | 23 K | (0.3) | 0 | 0 |
| Stock Based Compensation | 46.5 | 44.7 | 25.9 | 8.5 | 1.0 | 0.2 | 93 K |
| Other Operating Activities | 6.1 | 9.3 | 3.2 | 2.6 | 1.7 | 27 K | 0.3 |
| Change in Working Capital | (6.7) | 155.2 | 6.4 | 2.0 | (5.0) | 2.2 | 0.4 |
| Cash From Operations | (192.2) | (5.9) | (124.3) | (67.3) | (45.1) | (20.0) | (10.4) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (12.4) | (10.2) | (13.2) | (17.5) | (2.3) | (0.8) | (0.4) |
| Other Items | 80.7 | (215.4) | 28.1 | 75.2 | (200.9) | 0 | 0 |
| Cash From Investing Activities | 68.4 | (225.6) | 14.8 | 57.7 | (203.2) | (0.8) | (0.4) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | (1.6) | 0 | (0.3) | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 15.0 | 5.0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.5 | 1.4 | 2.5 | (0.9) | 348.9 | 34.7 | 8.1 |
| Cash From Financing Activities | 115.1 | 219.4 | 2.5 | 214.8 | 282.3 | 22.3 | 8.1 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (8.8) | (12.1) | (107.0) | 205.2 | 33.9 | 1.5 | (2.7) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (204.6) | (16.1) | (137.6) | (84.8) | (47.5) | (20.8) | (10.7) |